Calmark participates in a public tender for Region Stockholm
Calmark Sweden AB (publ) announced today that the Company is involved in a public procurement of bilirubinometers, initiated by Region Stockholm. If Calmark wins the tender, the estimated order value is approximately MSEK 2.5 over a period of four years. The delivery to the customer will be handled by a distributor.
Approximately 115,000 children are born in Sweden every year. Region Stockholm is the largest of the 21 counties, with approximately 28,000 childbirths. On August 31, 2022, an invitation to tender was published regarding bilirubinometers and NO meters (SLL527) and specifying the mandatory requirements. Based on the preliminary timetable, the award decision will be announced in November 2022.
“This tender has made us realize that we are unique and have a product that meets all the requirements set out by the healthcare system,” says Magdalena Tharaldsen, Calmark’s Director International Business Development. “Region Stockholm is important, not just because of its size, but also because of its influence on other regions in the country.”
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
Tags: